Viiv Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VIIV HLTHCARE, and what generic alternatives to VIIV HLTHCARE drugs are available?
VIIV HLTHCARE has twenty-six approved drugs.
There are twelve US patents protecting VIIV HLTHCARE drugs.
There are five hundred and fourteen patent family members on VIIV HLTHCARE drugs in fifty-nine countries and two hundred and eleven supplementary protection certificates in eighteen countries.
Summary for Viiv Hlthcare
International Patents: | 514 |
US Patents: | 12 |
Tradenames: | 19 |
Ingredients: | 17 |
NDAs: | 26 |
Drugs and US Patents for Viiv Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | EPZICOM | abacavir sulfate; lamivudine | TABLET;ORAL | 021652-001 | Aug 2, 2004 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-002 | Jan 21, 2021 | RX | Yes | Yes | 8,410,103 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Viiv Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-001 | Apr 4, 1997 | 5,563,142 | ⤷ Try a Trial |
Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 6,180,639*PED | ⤷ Try a Trial |
Viiv Hlthcare | JULUCA | dolutegravir sodium; rilpivirine hydrochloride | TABLET;ORAL | 210192-001 | Nov 21, 2017 | 8,101,629 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
International Patents for Viiv Hlthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Lithuania | 3372281 | ⤷ Try a Trial |
Japan | 2005507380 | ⤷ Try a Trial |
Taiwan | I315199 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Viiv Hlthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0434450 | 33/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: ''ABACAVIR'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER DERIVATS, EINSCHLIESSLICH ABACAVIR-SULFAT.; NAT. REGISTRATION NO/DATE: EU/1/99/112/001 EU/1/99/112/002 19990708; FIRST REGISTRATION: LI 55048 001, 55049 002 19990628 |
2465580 | 2190020-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CABOTEGRAVIR OR A PHAMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/20/1481 20201221 |
3808743 | CR 2022 00035 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ET FARMACEUTISK ACCEPTABELT ADDITIONSSALT AF RILPIVIRIN, HERUNDER RILPIVIRINHYDROCHLORID, OG EMTRICITABIN; REG. NO/DATE: EU/1/11/737/001-002 20111128 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.